Stock listing
Frankfurt:3G0 Altimmune, Inc. Aktie
German listing (Frankfurt) of Altimmune, Inc. · home listing NASDAQ:ALT
Follow Altimmune, Inc. into a list and get an email when it puts out news.
Share price · FWB:3G0
€1.20 EUR -0.07 (-5.7%)
Close on Nov 20, 2026
- Day range
- €1.20 – €1.25 EURNov 20, 2026
- Volume
- 3,100 sharesNov 20, 2026
- Market cap
- €233.8M EURAt the close on Nov 20, 2026 · price × 194.5M shares outstanding
- 52-week range
- €1.20 – €5.36 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €7,028 EURMedian day 0 shares · 36 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALT · Home | $1.33 USD | -0.06 (-4.3%) | 4,019,048 | $1.37 | $1.46 | $1.32 | $1.39 | Close on Nov 20, 2026 |
| Frankfurt:3G0 | €1.202 EUR | -0.072 (-5.7%) | 3,100 | €1.25 | €1.25 | €1.202 | €1.274 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:3G0 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €1.758 | +0.054 | +3.2% | €1.68 | €1.761 | €1.676 | 0 | |
| €1.704 | -0.115 | -6.3% | €1.829 | €1.843 | €1.70 | 2,706 | |
| €1.819 | +0.008 | +0.4% | €1.795 | €1.857 | €1.783 | 2,706 | |
| €1.811 | +0.012 | +0.7% | €1.785 | €1.827 | €1.775 | 0 | |
| €1.799 | -0.113 | -5.9% | €1.843 | €1.844 | €1.789 | 75 | |
| €1.912 | +0.026 | +1.4% | €1.899 | €1.914 | €1.891 | 100 | |
| €1.886 | +0.071 | +3.9% | €1.85 | €1.887 | €1.825 | 7,168 | |
| €1.815 | -0.007 | -0.4% | €1.815 | €1.815 | €1.815 | 1,292 | |
| €1.822 | +0.022 | +1.2% | €1.811 | €1.828 | €1.809 | 0 | |
| €1.80 | -0.103 | -5.4% | €1.858 | €1.877 | €1.789 | 15,936 | |
| €1.903 | -0.003 | -0.2% | €1.903 | €1.903 | €1.903 | 18,562 | |
| €1.906 | -0.104 | -5.2% | €1.906 | €1.906 | €1.906 | 0 | |
| €2.01 | +0.01 | +0.5% | €2.028 | €2.032 | €1.983 | 0 | |
| €2.00 | +0.077 | +4.0% | €1.936 | €2.002 | €1.929 | 0 | |
| €1.923 | -0.234 | -10.8% | €1.918 | €1.924 | €1.917 | 0 | |
| €2.157 | +0.102 | +5.0% | €2.157 | €2.157 | €2.157 | 0 | |
| €2.055 | -0.176 | -7.9% | €2.06 | €2.06 | €2.055 | 0 | |
| €2.231 | -0.059 | -2.6% | €2.20 | €2.302 | €2.199 | 4,150 | |
| €2.29 | -0.016 | -0.7% | €2.29 | €2.29 | €2.29 | 0 | |
| €2.306 | -0.059 | -2.5% | €2.306 | €2.306 | €2.306 | 2,000 | |
| €2.365 | +0.01 | +0.4% | €2.288 | €2.367 | €2.273 | 29,304 | |
| €2.355 | -0.029 | -1.2% | €2.355 | €2.355 | €2.355 | 22,132 | |
| €2.384 | +0.04 | +1.7% | €2.378 | €2.398 | €2.378 | 0 | |
| €2.344 | -0.047 | -2.0% | €2.346 | €2.347 | €2.327 | 0 | |
| €2.391 | -0.036 | -1.5% | €2.391 | €2.391 | €2.391 | 0 | |
| €2.427 | -0.054 | -2.2% | €2.433 | €2.433 | €2.423 | 4,590 | |
| €2.481 | -0.109 | -4.2% | €2.501 | €2.515 | €2.479 | 0 | |
| €2.59 | -0.021 | -0.8% | €2.59 | €2.59 | €2.59 | 0 | |
| €2.611 | +0.003 | +0.1% | €2.611 | €2.611 | €2.611 | 0 | |
| €2.608 | -0.062 | -2.3% | €2.608 | €2.608 | €2.608 | 0 | |
| €2.67 | -0.016 | -0.6% | €2.635 | €2.674 | €2.614 | 2,026 | |
| €2.686 | -0.098 | -3.5% | €2.76 | €2.769 | €2.684 | 0 | |
| €2.784 | -0.087 | -3.0% | €2.894 | €2.942 | €2.77 | 0 | |
| €2.871 | +0.059 | +2.1% | €2.777 | €2.872 | €2.767 | 0 | |
| €2.812 | +0.038 | +1.4% | €2.811 | €2.861 | €2.772 | 700 | |
| €2.774 | -0.059 | -2.1% | €2.777 | €2.777 | €2.767 | 2,086 | |
| €2.833 | +0.055 | +2.0% | €2.833 | €2.833 | €2.833 | 0 | |
| €2.778 | -0.036 | -1.3% | €2.778 | €2.778 | €2.778 | 0 | |
| €2.814 | -0.035 | -1.2% | €2.791 | €2.84 | €2.777 | 0 | |
| €2.849 | +0.064 | +2.3% | €2.774 | €2.866 | €2.757 | 0 | |
| €2.785 | +0.002 | +0.1% | €2.785 | €2.785 | €2.785 | 1,290 | |
| €2.783 | -0.053 | -1.9% | €2.783 | €2.783 | €2.783 | 0 | |
| €2.836 | -0.07 | -2.4% | €2.841 | €2.841 | €2.817 | 0 | |
| €2.906 | +0.051 | +1.8% | €2.89 | €2.908 | €2.883 | 0 | |
| €2.855 | +0.008 | +0.3% | €2.855 | €2.855 | €2.855 | 0 | |
| €2.847 | +0.081 | +2.9% | €2.734 | €2.857 | €2.73 | 24,096 | |
| €2.766 | +0.19 | +7.4% | €2.766 | €2.766 | €2.766 | 0 | |
| €2.576 | -0.059 | -2.2% | €2.576 | €2.576 | €2.576 | 0 | |
| €2.635 | +0.027 | +1.0% | €2.635 | €2.635 | €2.635 | 0 | |
| €2.608 | -0.211 | -7.5% | €2.608 | €2.608 | €2.608 | 2,000 | |
| €2.819 | +0.163 | +6.1% | €2.722 | €2.824 | €2.707 | 3,134 | |
| €2.656 | -0.022 | -0.8% | €2.656 | €2.656 | €2.656 | 0 | |
| €2.678 | +0.099 | +3.8% | €2.678 | €2.678 | €2.678 | 0 | |
| €2.579 | -0.058 | -2.2% | €2.579 | €2.579 | €2.579 | 0 | |
| €2.637 | +0.175 | +7.1% | €2.637 | €2.637 | €2.637 | 0 | |
| €2.462 | -0.142 | -5.5% | €2.462 | €2.462 | €2.462 | 26,398 | |
| €2.604 | +0.107 | +4.3% | €2.604 | €2.604 | €2.604 | 0 |
Splits
2 splits since 2017 · FWB:3G0 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- Frankfurt:3G0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 19, 2026
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Latest earnings call · Nov 12, 2026
Altimmune (NASDAQ:ALT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Technical Presentation (November 2026)
Technical · 17 slides
Latest news
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
Nov 5, 2026
Closed €1.76 (+3.2%) on Nov 6, 2026
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Nov 5, 2026
Closed €1.70 (-6.3%) on Nov 5, 2026
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
Oct 27, 2026
Closed €1.82 (+1.2%) on Oct 27, 2026
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Oct 19, 2026
Closed €1.92 (-10.8%) on Oct 19, 2026
Altimmune to Participate in Stifel Cardiometabolic Forum
Sep 23, 2026
Closed €2.78 (-3.0%) on Sep 23, 2026
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
Sep 3, 2026
Closed €2.77 (+7.4%) on Sep 3, 2026
Altimmune, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 179 in all · newest Nov 19, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 12, 2026
- Decks
- 31 decks · latest Nov 9, 2026
Where Altimmune, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALT · Home listing | NASDAQ | United States | USD |
| gettex:3G0 | gettex | Germany | EUR |
| Lang & Schwarz:A2N5Z6 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2N5Z6 | LS Exchange | Germany | EUR |
| BMV:ALT1 | BMV | Mexico | MXN |
| BIVA:ALT1 | BIVA | Mexico | MXN |
| Tradegate:3G0 | Tradegate | Germany | EUR |
| BOATS:ALT | BOATS | United States | USD |
| LSE:0A4C | LSE | United Kingdom | USD |
| Dusseldorf:3G0 | Dusseldorf | Germany | EUR |
| Frankfurt:3G0 · This page | Frankfurt | Germany | EUR |
| Hamburg:3G0 | Hamburg | Germany | EUR |
| Munich:3G0 | Munich | Germany | EUR |
| Stuttgart:3G0 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.6× against a median of 2.0×: the lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $28.73M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.55
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.5M | US$243.4M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.4M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Median of the others | US$257.8M | US$128.0M | 21.8× | 2.0× | −196.0% | 0.1× | 1.48 |
Forecasts
7 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.67 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.62 · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jerome Durso | President, Chief Executive Officer and Chairman Of The Board |
| Greg Weaver | Chief Financial Officer |
| Robin E. Abrams | Chief Legal Officer |
| Christophe Arbet-Engels | Chief Medical Officer |
| Linda M. Richardson | Chief Commercial Officer |
| Scot Roberts | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Jerome Durso | President, Chief Executive Officer and Chairman Of The Board |
| Alex Howarth | Director |
| Catherine Angell Sohn | Director |
| Diane K. Jorkasky | Director |
| John M. Gill | Director |
| Mitchel Sayare | Director |
| Peter Greenleaf | Director |
| Philip Hodges | Director |
| Teri Lawver | Director |
| Wayne Pisano | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Altimmune (NASDAQ:ALT) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2026 Earnings Call | Wed, Aug 12, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q1 2026 Earnings Call | Wed, May 13, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q3 2025 Earnings Call | Thu, Nov 06, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2025 Earnings Call | Tue, Aug 12, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q1 2025 Earnings Call | Tue, May 13, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q4 2024 Earnings Call | Thu, Feb 27, 2025 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 8:30 AM ET | Replay |
| Altimmune (NASDAQ:ALT) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −16.6% |
| Q2 2026 | Aug 12, 2026 · Before open | −2.3% |
| Q1 2026 | May 13, 2026 · Before open | −1.9% |
| Q4 2025 | Mar 26, 2026 | −8.8% |
| Q3 2025 | Nov 6, 2025 · Before open | +5.1% |
| Q2 2025 | Aug 12, 2025 · Before open | +7.1% |
| Q1 2025 | May 13, 2025 · Before open | −4.2% |
| Q4 2024 | Mar 25, 2025 · Before open | −2.6% |
| Q3 2024 | Nov 12, 2024 · Before open | +29.1% |
| Q2 2024 | Aug 8, 2024 · Before open | +15.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | +7.8% |
| Q4 2023 | Mar 27, 2024 · Before open | +2.8% |
| Q3 2023 | Nov 7, 2023 · Before open | +1.1% |
| Q2 2023 | Aug 10, 2023 · Before open | +3.0% |
| Q1 2023 | May 11, 2023 · Before open | +7.0% |
| Q4 2022 | Feb 28, 2023 · Before open | +6.4% |
| Q3 2022 | Nov 10, 2022 · Before open | +9.2% |
| Q2 2022 | Aug 11, 2022 · After close | +26.1% |
| Q1 2022 | May 12, 2022 · Before open | +8.6% |
| Q4 2021 | Mar 15, 2022 · Before open | −8.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 17 slides | Nov 9, 2026 |
| AASLD The Liver Meeting 2026 | Conference | 19 slides | Nov 8, 2026 |
| Technical Presentation (November 2026) | Technical | 16 slides | Nov 7, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 38 slides | Aug 12, 2026 |
| Technical Presentation (July 2026) | Technical | 19 slides | Jul 28, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 32 slides | Mar 5, 2026 |
| Technical Presentation (December 2025) | Technical | 20 slides | December 2025 |
| Technical Presentation (June 2025) | Technical | 23 slides | Jun 26, 2025 |
| Investor Presentation (May 2025) | Investor deck | 39 slides | May 2025 |
| Technical Presentation (November 2023) | Technical | 19 slides | Nov 30, 2023 |
All 31 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and accompanying common stock warrants (or pre-funded warrants in lieu thereof) Closed: US$225M raised · US$3 a share · Warrants at US$3 · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Barclays (co-lead), Titan Partners (co-lead) Buyers: Deep Track Capital (led the financing); TCGX; Viking Global Investors; RA Capital Management Use of proceeds: Fund the upcoming Phase 3 trial in MASH, plus working capital and general corporate purposes | Apr 27, 2026 |
| Registered direct offering of common stock (or pre-funded warrants in lieu thereof) Closed: US$75M raised · Titan Partners, a division of American Capital Partners Dealers: Titan Partners, a division of American Capital Partners (lead) Buyers: new fundamental institutional investor (17,045,454 shares of common stock (or pre-funded warrants in lieu thereof)) Use of proceeds: Upcoming Phase 3 trial in MASH, working capital and general corporate purposes | Jan 29, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41.0K | 20.0K | 426.0K | -68.0K | 4.41M | 8.19M | 5.80M | 10.3M | 10.7M | 3.24M |
| Cost of revenue | 112.0K | 238.0K | 477.0K | 500.0K | 73.8M | 33.5M | 17.1M | 18.5M | 18.4M | 7.22M |
| Gross profit | 41.0K | 20.0K | 426.0K | -68.0K | 4.41M | -25.3M | 5.80M | -8.13M | -18.4M | -1.99M |
| Research and development | 66.4M | 82.2M | 65.8M | 70.5M | 74.5M | 49.8M | 17.8M | 18.5M | 18.4M | 7.22M |
| Selling, general and administrative | 28.1M | 21.0M | 18.1M | 17.1M | 15.4M | 13.2M | 8.50M | 9.77M | 8.46M | 11.5M |
| Operating income | -94.5M | -103.2M | -95.9M | -87.7M | -96.9M | -54.8M | -21.5M | -42.8M | -52.0M | -11.1M |
| Depreciation and amortization | 112.0K | 238.0K | 477.0K | -205.0K | 551.3K | 428.9K | 387.3K | 218.7K | 83.8K | 63.1K |
| EBITDA | -94.4M | -102.9M | -95.5M | -87.9M | -96.4M | -54.4M | -21.1M | -42.6M | -52.0M | -11.0M |
| Interest expense | 1.64M | 9.00K | 35.0K | 8.00K | 5.00K | 9.42K | 2.24K | 297.1K | 162.1K | 38.5K |
| Income before tax | -88.8M | -95.1M | -88.4M | -84.9M | -97.1M | -54.5M | -20.6M | -45.3M | -52.1M | -11.1M |
| Income tax | -681.0K | 309.1K | -197.0K | -919.5K | -5.42M | -58.5K | -6.15M | -5.64M | 0 | |
| Net income | -88.1M | -95.1M | -88.4M | -84.7M | -97.1M | -49.0M | -20.5M | -39.2M | -46.4M | -11.1M |
| Earnings per share, basic | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 | -118.91 | 2.97 |
| Earnings per share, diluted | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 | -118.91 | 2.95 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 43.8M | 36.9M | 135.1M | 111.1M | 190.3M | 115.9M | 8.96M | 33.7M | 8.77M | 2.88M |
| Short-term investments | 229.7M | 95.0M | 62.7M | 73.8M | 0 | 100.0M | 28.3M | 3.53M | 66.8M | |
| Receivables | 1.74M | 3.12M | 4.85M | 2.54M | 5.84M | 12.4M | 1.65M | 4.47M | 10.2M | 999.1K |
| Inventory | 34.0K | -13.4B | -1.96B | -503.9M | 3.53M | 0 | ||||
| Current assets | 278.2M | 137.3M | 209.6M | 192.8M | 204.1M | 230.3M | 39.4M | 39.4M | 23.5M | 4.49M |
| Property, plant and equipment | 312.0K | 413.0K | 651.0K | 1.08M | 1.45M | 1.06M | 1.10M | 1.34M | 603.1K | 177.9K |
| Goodwill | 0 | 0 | 0 | 18.8M | ||||||
| Total assets | 279.9M | 139.3M | 210.6M | 206.9M | 218.9M | 245.1M | 54.1M | 54.8M | 63.0M | 38.4M |
| Accounts payable | 2.72M | 211.0K | 2.07M | 4.80M | 2.03M | 612.3K | 18.2K | 372.9K | 129.1K | 2.01M |
| Current liabilities | 15.0M | 10.5M | 12.1M | 17.1M | 18.3M | 12.0M | 3.92M | 4.53M | 3.84M | 5.47M |
| Long-term debt | 34.3M | 4.58M | 1.45M | 1.83M | 1.86M | 1.85M | 4.57M | 526.0K | ||
| Total debt | 34.3M | 1.68M | 671.0K | 4.58M | 1.45M | 1.83M | 1.86M | 572.8K | 599.9K | 526.0K |
| Total liabilities | 55.0M | 15.8M | 16.5M | 21.6M | 19.7M | 19.2M | 8.54M | 6.44M | 14.4M | 6.19M |
| Shareholders' equity | 224.9M | 123.5M | 194.1M | 185.3M | 199.1M | 225.9M | 45.5M | 48.3M | 39.4M | 32.2M |
| Shares outstanding | 110.9M | 72.4M | 70.7M | 49.2M | 41.0M | 37.1M | 15.3M | 9.08M | 608.5K | 6.92M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -67.5M | -79.8M | -75.8M | -62.6M | -78.2M | -34.3M | -9.60M | -9.39M | -20.2M | -6.35M |
| Capital spending | -11.0K | 0 | -47.0K | -126.0K | -12.1M | -204.0K | -1.23K | -975.4K | -112.4K | -125.0K |
| Free cash flow | -67.5M | -79.8M | -75.9M | -62.7M | -90.4M | -34.5M | -9.60M | -10.4M | -20.3M | -6.48M |
| Cash from investing | -132.5M | -28.4M | 13.7M | -73.4M | 87.5M | -72.2M | -28.3M | -1.00M | 13.7M | -220.6K |
| Cash from financing | 206.8M | 10.0M | 86.1M | 56.8M | 65.1M | 213.5M | 12.5M | 32.5M | 15.8M | 4.98M |
| Dividends paid | -135.5M | -3.79B | -22.9K | 0 | 0 | |||||
| Share buybacks | 291.0K | 300.0K | 215.0K | -516.0K | 224.5M | 135.5M | 3.79B | -2.39M | 13.0M | 3.80M |
| Change in cash | 6.83M | -98.2M | 24.0M | -79.2M | 74.4M | 107.0M | -25.4M | 22.0M | 9.43M | 138.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 29, 2026 | Financing | SEC |
| 8-K · Current report | Oct 27, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Jul 28, 2026 | Current report | SEC |
| 8-K · Current report | Jun 16, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | May 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | May 1, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 24, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Apr 23, 2026 | Offer document | SEC |
| S-3MEF | Apr 22, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Apr 22, 2026 | Offer document | SEC |
| 8-K · Current report | Apr 16, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Apr 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Mar 17, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 17, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 9, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Mar 6, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 6, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Feb 6, 2026 | Offer document | SEC |
| 4 · Change in ownership | Feb 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 28, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 28, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 19, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Dec 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2025 | Management or board change | SEC |
| S-3/A · Registration statement, amended | Nov 13, 2025 | Offer document | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| S-3 · Registration statement | Nov 6, 2025 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 6, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 17, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2025 | Other filings | SEC |
| ARS · Annual report to shareholders | Aug 15, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 15, 2025 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Aug 12, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Aug 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 14, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Mar 11, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 5, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 27, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Feb 27, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 25, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 8-K · Current report | Nov 12, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 17, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 30, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 15, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 15, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 15, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jul 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 26, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Apr 10, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Mar 5, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2024 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Altimmune, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 194,589,451
- Fully diluted
- 194,589,451
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 194,589,451 | Nov 6, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$3.00 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 194,589,451 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Catherine Angell Sohn Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Axcella Health Inc (Director · Aug 21, 2019 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Palisade Bio, Inc. (Director · Jan 13, 2014 – Jul 1, 2015 · Past); Lifecore Biomedical, Inc. (Director · Nov 13, 2012 – Jun 4, 2022 · Past); Jazz Pharmaceuticals plc (Director · Jul 27, 2012 – Aug 11, 2023 · Past) | Director · Since at least Mar 23, 2023 |
| Derace L Schaffer Other companies: Lantheus Holdings, Inc. (Director · Mar 4, 2016 – Mar 3, 2020 · Past); American Caresource Holdings Inc (Director · Jul 20, 2010 – Jun 14, 2012 · Past); King Pharmaceuticals Inc (Director · May 14, 2010 – Jan 31, 2011 · Past) | Director · May 17, 2010 – Dec 28, 2017 · Past |
| Richard I Eisenstadt Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Mar 31, 2021 – Mar 31, 2021 · Past); Neos Therapeutics Inc (Chief Financial Officer · Mar 2, 2020 – Mar 19, 2021 · Past) | Chief Financial Officer · Dec 31, 2021 – Jan 30, 2024 · Past |
| Vipin K Garg Other companies: Neos Therapeutics Inc (Chief Executive Officer · Jul 22, 2015 – Mar 1, 2018 · Past); Ocera Therapeutics Inc (President & CEO, Director · Apr 1, 2011 – Aug 7, 2012 · Past) | Director · Since at least Nov 30, 2018 |
| Wayne Pisano Other companies: Oncolytics Biotech Inc. (Director · Since at least Jun 26, 2025); Provention Bio Inc (Director · Jul 3, 2018 – Apr 27, 2023 · Past) | Director · Since at least Aug 30, 2018 |
| Gregory L Weaver Other companies: Atossa Therapeutics, Inc. (Former EVP, CFO, & Director, Director · May 17, 2019 – Nov 15, 2023 · Past) | Chief Financial Officer · Since at least Nov 11, 2024 |
| John M. Gill Other companies: Tetralogic Pharmaceuticals Corp (Director · Dec 11, 2013 – Dec 31, 2013 · Past) | Director · Since at least Jun 11, 2013 |
| Alex Howarth | Director · Since at least Oct 27, 2026 |
| Christophe Arbet-Engels | Chief Medical Officer · Since at least Aug 3, 2026 |
| David Drutz | Director · May 4, 2017 – Aug 19, 2024 · Past |
All 28 people
| Person | Seat |
|---|---|
| Diane K. Jorkasky | Director · Since at least Nov 5, 2026 |
| Francesca M Cook | SVP, Policy & Gov't Affairs · Dec 1, 2011 – Dec 8, 2014 · Past |
| Greg Weaver | Chief Financial Officer · Since at least Sep 15, 2025 |
| Jeffrey Michael Jones | COO · Mar 11, 2015 – Mar 11, 2015 · Past |
| Jerome Durso | President, Chief Executive Officer and Chairman Of The Board · Since at least Aug 13, 2026 |
| Joel McCleary | Director · Jun 23, 2010 – Dec 31, 2014 · Past |
| Klaus Schafer | Director · Since at least May 4, 2017 |
| Linda M. Richardson | Chief Commercial Officer · Since at least Nov 6, 2025 |
| Matthew Scott Harris | Chief Medical Officer · Since at least Sep 9, 2019 |
| Mitchel Sayare | Director · Since at least Oct 27, 2026 |
| Peter Greenleaf | Director · Since at least Oct 27, 2026 |
| Philip Hodges | Director · Since at least Nov 4, 2026 |
| Philip Hodges | Director · Since at least May 4, 2017 |
| Richard Thomas Menziuso | Principal Accounting Officer · Since at least Nov 18, 2026 |
| Robin E. Abrams | Chief Legal Officer · Since at least Nov 6, 2025 |
| Scot Roberts | Chief Scientific Officer · Since at least May 4, 2017 |
| Teri Lawver | Director · Since at least Feb 25, 2025 |
| Thomas Richard Fuerst | EVP, Chief Scientific Officer · Apr 5, 2010 – Dec 1, 2011 · Past |
Log in to ask 6ix AI your own questions about Altimmune, Inc.